ALA-1000, a 3-month Buprenorphine released injectable for treating opioid use disorder and chronic pain

Booth No: S610

Characteristic

ALA-1000 is the first, three-month Buprenorphine long-acting injectable (LAI) administered subcutaneously entering the clinical stage globally. Single-ascending-dose (SAD) clinical study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. ALA-1000 injection benefits patients by reducing the burden of daily administration, improving patient compliance, and diminishing the concerns of misuse, abuse, and accidental pediatric exposure. The lower dose of ALA-1000 is applicable for treating chronic pain including cancer pain, low back pain, and osteoarthritis pain.

Menu

ALA-1000, a 3-month Buprenorphine released injectable for treating opioid use disorder and chronic pain

Characteristic

Other Products

Products you may be interested in

Highest Rated Products